Table 1.
| Table 1A. Demographic variables in patients with unresectable HCC treated with TACE, Y90 or no treatment | |||
|---|---|---|---|
| Variable | TACE pt. number (%) |
Y90 pt. number (%) |
p-value |
| Total group | 691 (100) | 99 (100) | |
| Males | 518 (75) | 70 (70) | ns |
| Females | 173 (25) | 29 (30) | ns |
| Alcohol | 217 (31) | 37 (37) | ns |
| Tobacco | 101 (15) | 19 (19) | ns |
| HBV only | 97 (14) | 9 (9) | ns |
| HCV only | 132 (19) | 30 (30) | 0.057 |
| Cirrhosis | 462 (66) | 80 (80) | ns |
| Table 1B. Clinical variables in patients with unresectable HCC treated with either TACE, Y90 or no treatment | |||
|---|---|---|---|
| Variable | TACE pt. number (%) |
Y90 pt. number (%) |
p-value |
| Total group | 691 (100) | 99 (100) | |
| Tumor Number ≥5 | 257 (37) | 26 (26) | ns |
| Bilobar disease | 354 (51) | 43 (43) | ns |
| Portal Vein Thrombosis (PVT) | 295 (42) | 28 (28) | 0.08 |
| Alpha-fetoprotein ≥25 ng/ml | 465 (67) | 58 (58) | ns |
| Bilirubin ≥1.5 mg/dL | 173 (25) | 13 (13) | 0.044 |
| Album in <3.5 g/dL | 449 (65) | 66 (66) | ns |